GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » PT Millennium Pharmacon International Tbk (ISX:SDPC) » Definitions » Debt-to-EBITDA

PT Millennium Pharmacon International Tbk (ISX:SDPC) Debt-to-EBITDA : 6.48 (As of Sep. 2024)


View and export this data going back to 1990. Start your Free Trial

What is PT Millennium Pharmacon International Tbk Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

PT Millennium Pharmacon International Tbk's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was Rp777,517 Mil. PT Millennium Pharmacon International Tbk's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was Rp43,113 Mil. PT Millennium Pharmacon International Tbk's annualized EBITDA for the quarter that ended in Sep. 2024 was Rp126,572 Mil. PT Millennium Pharmacon International Tbk's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was 6.48.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for PT Millennium Pharmacon International Tbk's Debt-to-EBITDA or its related term are showing as below:

ISX:SDPC' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 5.5   Med: 6.11   Max: 6.97
Current: 6.44

During the past 13 years, the highest Debt-to-EBITDA Ratio of PT Millennium Pharmacon International Tbk was 6.97. The lowest was 5.50. And the median was 6.11.

ISX:SDPC's Debt-to-EBITDA is ranked worse than
86.75% of 83 companies
in the Medical Distribution industry
Industry Median: 2.15 vs ISX:SDPC: 6.44

PT Millennium Pharmacon International Tbk Debt-to-EBITDA Historical Data

The historical data trend for PT Millennium Pharmacon International Tbk's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Millennium Pharmacon International Tbk Debt-to-EBITDA Chart

PT Millennium Pharmacon International Tbk Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.97 5.64 6.21 6.21 5.71

PT Millennium Pharmacon International Tbk Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.86 5.88 6.06 6.21 6.48

Competitive Comparison of PT Millennium Pharmacon International Tbk's Debt-to-EBITDA

For the Medical Distribution subindustry, PT Millennium Pharmacon International Tbk's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Millennium Pharmacon International Tbk's Debt-to-EBITDA Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PT Millennium Pharmacon International Tbk's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where PT Millennium Pharmacon International Tbk's Debt-to-EBITDA falls into.



PT Millennium Pharmacon International Tbk Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

PT Millennium Pharmacon International Tbk's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(665417.764 + 44918.216) / 124507.869
=5.71

PT Millennium Pharmacon International Tbk's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(777517.168 + 43112.528) / 126572.464
=6.48

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


PT Millennium Pharmacon International Tbk  (ISX:SDPC) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


PT Millennium Pharmacon International Tbk Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of PT Millennium Pharmacon International Tbk's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Millennium Pharmacon International Tbk Business Description

Traded in Other Exchanges
N/A
Address
Jalan.Sultan Iskandar Muda No 18, Crown Bungur Arteri Lantai 2-4th Floors, Jakarta, IDN, 12240
PT Millennium Pharmacon International Tbk is engaged in distributing medicines, food supplements, and medical disposables. The operating segments of the group are Prescription medicine, Non-prescription medicine, and Medical devices, of which the majority of the revenue is derived from the Prescription Medicine segment.. The company's geographical segments are Java, Sumatera, Kalimantan, Sulawesi, and Bali.

PT Millennium Pharmacon International Tbk Headlines

No Headlines